Medicine That Matters: An Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing